Institute of Medical Biology -Chinese Academy of Medical Sciences
Kunming, Yunnan, 650118, China
NCT Number: NCT01949857
The purpose of this Phase 4 trial is to assess the safety, immunogenicity, three-year immune persistence of inactivated hepatitis A vaccine (HAV) and live attenuated HAV vaccine.
Looking for future studies?
Notify Me18 month–65 year
All sexes
Interventional
Phase 4
Kunming, Yunnan, 650118, China
Hepatitis A refers to liver inflammation caused by infection with the hepatitis A virus. HAV is is one of the most common hepatitis viruses that can cause hepatitis in China. The data from the phase 1, 2 and 3 trials suggested that both inactivated hepatitis A vaccine and live attenuated hepatitis A vaccine had a clinically acceptable safety and good immunogenicity for healthy Chinese people.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
Other names: Hepatitis A (Live) Vaccine, Freeze-dried
6.50 lgCCID50/Vial in babies aged 18-35 months\\6.50 lgCCID50/Vial in children aged 3-15 years \\6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
Other names: Hepatitis A Vaccine
320EU/Vial in babies aged 18-35 months\\320EU/Vial in children aged 3-15 years \\640EU/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose
Other names: Hepatitis A Vaccine, Inactivated
250U/Vial in babies aged 18-35 months\\250U/Vial in children aged 3-15 years \\500U/Vial in adults aged 16 up to 65 years old\\boost at month 6\\two-dose.
Other names: Hepatitis A Vaccine, Inactivated
Time frame: up to 43 months
Time frame: up to 43 months
compare frequency of all the solicited events, unsolicited adverse events and serious adverse events between vaccine group and placebo group.
Institute of Medical Biology, Chinese Academy of Medical Sciences
Other
Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine
Acronym: HAV
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06576024
Blood-Borne Infections, Communicable Diseases
Liuzhou, Guangxi, China
View Trial DetailsNCT06298708
Digestive System Diseases, Enterovirus Infections
Chiang Mai, Thailand
View Trial DetailsNCT03312699
Bacterial Infections, Bacterial Infections and Mycoses
Stanford, California, United States
View Trial DetailsNCT00139113
Digestive System Diseases, Enterovirus Infections
Anchorage, Alaska, United States
View Trial Details